Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

References

• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892–909
   PubMed Web of Science ®Google Scholar
• Blackwell B. From compliance to alliance. A quarter century of research. Neth J Med 1996;48:140–9
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl 16):10–3
   Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49: 196–201
   PubMed Web of Science ®Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121–8
   PubMed Web of Science ®Google Scholar
• Auiler JF, Liu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr Med Res Opin 2002;18:311–6
   PubMed Web of Science ®Google Scholar
• Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 2000;21: 23–31
   PubMed Web of Science ®Google Scholar
• Schug BS, Brendel E, Chantraine E, et al. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br J Clin Pharmacol 2002;53:582–8
   PubMed Web of Science ®Google Scholar
• Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64:1987–91
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Cummings DM, Amadio Jr P, Nelson L, Fitzgerald JM. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med 1991;151:250–9
   PubMed Web of Science ®Google Scholar
• Frishman WH, Charlap S, Ocken S, Spivack C. Calcium-channel blockers and systemic hypertension. J Clin Hypertens 1985;1:107–22
   PubMedGoogle Scholar
• Michalewicz L, Messerli FH. Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol 1997;79:39–46 [discussion 47–8]
   Google Scholar
• Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326–31
   Google Scholar
• Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet 1996;30(1):28–51
   Google Scholar
• Chung M, Reitberg DP, Gaffney M, Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am J Med 1987;83:10–4
   Google Scholar
• Mohiuddin S, Hilleman D. Substituting nifedipine-GITS for immediate-release calcium channel antagonists in patients with stable angina pectoris. Curr Ther Res 1991;50:546–52
   Web of Science ®Google Scholar
• van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: pharmacological aspects. J Hypertens Suppl 1993;11:S3–S11
   Google Scholar
• Glasser SP. Circadian variations and chronotherapeutic implications for cardiovascular management: a focus on COER verapamil. Heart Dis 1999;1:226–32
   PubMedGoogle Scholar
• White WB. A chronotherapeutic approach to the management of hypertension. Am J Hypertens 1996;9:29S–33S
   Google Scholar
• White WB, Sica DA, Calhoun D, et al. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J 2002;144:657–65
   PubMed Web of Science ®Google Scholar
• Quinn L. Type 2 diabetes: epidemiology, pathophysiology, and diagnosis. Nurs Clin North Am 2001;36:175–92
   PubMed Web of Science ®Google Scholar
• ADA. National diabetes fact sheet. In: American Diabetes Association; 2005, http://diabetes.org/diabetes-statistics/ national-diabetes-fact-sheet.jsp
   Google Scholar
• DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281–303
   PubMed Web of Science ®Google Scholar
• Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety, and dose–response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials [The Glipizide Gastrointestinal Therapeutic System Study Group]. Diabetes Care 1997;20:597–606
   Google Scholar
• Berger W. [Diabetic emergencies]. Schweiz Rundsch Med Prax 1997;86:308–13
   Google Scholar
• Chung M, Kourides I, Canovatchel W, et al. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. J Clin Pharmacol 2002;42:651–7
   PubMed Web of Science ®Google Scholar
• Berelowitz M, Fischette C, Cefalu W, et al. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994;17:1460–4
   PubMed Web of Science ®Google Scholar
• Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95: 68–71
   Google Scholar
• Dutkiewics S. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 2001;32:423–32
   PubMedGoogle Scholar
• Schwinn DA, Price DT, Narayan P. Alpha-1-adrenoceptor subtype selectivity and lower urinary tract symptoms. Mayo Clin Proc 2004;79: 1423–34
   Google Scholar
• NKUDIC. Prostate enlargement: benign prostatic hyperplasia. In: National kidney and urologic diseases information clearing-house; 2005. http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/
   Google Scholar
• Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999;48:678–87
   PubMed Web of Science ®Google Scholar
• Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients [The Multicenter Study Group]. J Urol 1997;157:525–30
   PubMed Web of Science ®Google Scholar
• Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49: 295–320
   Google Scholar
• Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000;38:400–9
   Google Scholar
• Fitzpatrick JM, Desgrandchamps F. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. Br J Urol Int 2005;95:575–9
   Google Scholar
• Kirby RS, Andersen M, Gratzke P, et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Br J Urol Int 2001;87:192–200
   Google Scholar
• Serels S. The wet patient: understanding patients with over-active bladder and incontinence. Curr Med Res Opin 2004;20: 791–801
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988–93
   PubMedGoogle Scholar
• Cannon TW, Chancellor MB. Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol 2002;45:205–17
   PubMed Web of Science ®Google Scholar
• Gupta SK, Sathyan G. Pharmacokinetics of an oral once-aday controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999;39: 289–96
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs 2004;64:885–912
   Google Scholar
• Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997;157: 1093–7
   Google Scholar
• Sathyan G, Dmochowski RR, Appell RA, et al. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Clin Pharmacokinet 2004;43: 1059–68
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chen A, Sathyan G, et al. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. J Clin Pharmacol 2005;45:961–8
   PubMed Web of Science ®Google Scholar
• Sathyan G, Hu W, Chancellor MB, Gupta SK. Comparison of CYP3A4 inhibitor effects on the stereoselective pharmacokinetics of extended release oxybutynin and conventional oxybutynin. Pharm Sci 1999;1:2056
   Google Scholar
• Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence [OROS Oxybutynin Study Group]. J Urol 1999;161:1809–12
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence [The Ditropan XL Study Group]. Obstet Gynecol 2000;95:718–21
   PubMed Web of Science ®Google Scholar
• Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002;34:43–9
   PubMedGoogle Scholar
• Kane J, Kramer M, Ford L, et al. Treatment of patients with acute schizophrenia using paliperidone extended-release tablets: a 6-week placebo controlled study. Neuropsychopharmacology 2005;30:S200
   Google Scholar
• Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and effect on functioning of paliperidone extended-release tablets in schizophrenia: an international 6-week placebo-controlled study. Schizophr Res 2006;81:S43
   Web of Science ®Google Scholar
• Marder S, Kramer M, Ford L, et al. Efficacy and tolerability of two fixed doses of paliperidone extended-release tablets in the treatment of acute schizophrenia: a 6-week placebo controlled study. Neuropsychopharmacology 2005;30:S191–S192
   Google Scholar
• Wallace M, Hewitt D, Khanna S, Thipphawong J. Efficacy and safety evaluation of OROS hydromorphone in patients with chronic low back pain. Poster presented at the 11th World Congress on Pain, Sydney, Australia, 21–26 August 2005 [Poster No. 127]
   Google Scholar
• Roth S, Damask M, Khanna S, Thipphawong J. To evaluate the efficacy and safety of OROS hydromorphone versus extended-release oxycodone for the management of moderate to severe chronic pain in patients with osteoarthritis of the knee or hip, regularly using NSAIDS with or without the addition of opioid analgesia. Poster presented at the 11th World Congress on Pain, Sydney, Australia, 21–26 August 2005 [Poster No.103]
   Google Scholar
• Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004;18:243–50
   PubMed Web of Science ®Google Scholar
• US DHHS. Mental health: a Report of the Surgeon General. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health 1999
   Google Scholar
• Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004;18:1011–30
   PubMed Web of Science ®Google Scholar
• Biederman J. Attention-deficit/hyperactivity disorder: a lifespan perspective. J Clin Psychiatry 1998;59(Suppl 7):4–16
   Google Scholar
• Swanson J. Compliance with stimulants for attention-deficit/ hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003;17:117–31
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909–18
   PubMed Web of Science ®Google Scholar
• Pelham Jr WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987;80:491–501
   PubMed Web of Science ®Google Scholar
• Dulcan M. Using psychostimulants to treat behavioral disorders in children and adolescents. J Child Adolesc Psychopharmacol 1990;1:7–20
   PubMedGoogle Scholar
• Keating GM, McClellan K, Jarvis B. Methylphenidate (OROS formulation). CNS Drugs 2001;15:495–500 [discussion 501–3]
   Google Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:E105
   Google Scholar
• Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:883–92
   PubMed Web of Science ®Google Scholar
• Loney J, Milich R. Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M, Routh D, editors. Advances in developmental and behavioral pediatrics. Greenwich: JAI Press; 1982. p. 113–47
   Google Scholar
• Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003;42:424–33
   PubMed Web of Science ®Google Scholar
• Baren M, Swanson J, Wigal S, et al. Lack of effect of different breakfast conditions on the pharmacokinetics and efficacy of OROS methylphenidate HCl extended-release tablets in children with ADHD [abstract]. Pediatr Res 2000;47: 23A
   Web of Science ®Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004;113: e206–16
   PubMed Web of Science ®Google Scholar
• NIMH. Schizophrenia. In: National Institute of Mental Health; 1999. http://www.nimh.nih.gov/publicat/schizoph.cfm
   Google Scholar
• Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991;48:978–86
   Google Scholar
• Rund BR, Borg NE. Cognitive deficits and cognitive training in schizophrenic patients: a review. Acta Psychiatr Scand 1999;100:85–95
   PubMed Web of Science ®Google Scholar
• APA. Practice guideline for the treatment of patients with bipolar disorder [revision]. Am J Psychiatry 2002;159(Suppl 4):1–50
   Google Scholar
• Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653–64
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637–51
   Google Scholar
• Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000;102:83–6
   Google Scholar
• Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;60(Suppl 23):20–4
   PubMedGoogle Scholar
• Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514–20
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl 16):18–23
   PubMed Web of Science ®Google Scholar
• Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62:153–7
   PubMed Web of Science ®Google Scholar
• Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003;25:169–78
   PubMed Web of Science ®Google Scholar
• Vallner JJ, Stewart JT, Kotzan JA, et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981;21:152–6
   PubMed Web of Science ®Google Scholar
• Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002;97:827–36
   PubMed Web of Science ®Google Scholar
• Sathyan G, Xu E, Gupta S. Effect of food on the pharmacokinetic profile of OROS hydromorphone. Poster presented at the 11th World Congress on Pain, Sydney, Australia, 21–26 August 2005 [Poster No. 132]
   Google Scholar
• Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study. Drug Saf 2002;25:1021–33
   Google Scholar